|Table of Contents|

Research progress of immunotherapy for pancreatic carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

2017 10
Research Field:
Publishing date:


Research progress of immunotherapy for pancreatic carcinoma
Song YilinLiu ZejieYang JingLi JunqiangFeng YingmingSu Haichuan
Department of Oncology,Tangdu Hospital,The Fourth Military Medical University,Shaanxi Xi'an 710038,China.
pancreatic cancerimmunotherapyT cellcheckpoint inhibitors
Pancreatic cancer is one of the most lethal malignancies resistant to conventional therapies.Most of the patients initially diagnosed with locally advanced or metastatic disease which has poor prognosis.Despite chemotherapy regimens such as nab-paclitaxel and gemcitabine or 5-fluorouracil/leucovorin/oxaliplatin,traditional therapeutic methods offer a modest survival benefit.Therefore,urgent need for exploring new immunotherapies turns to the center stage of treatments for pancreatic cancer treatment.Current researches on pancreatic cancer immunotherapy mainly focus on the following aspects:checkpoint inhibitors,vaccines,adoptive T cells therapy,monoclonal antibodies,and cytokines.In this article,we review the available studies concerning multiple aspects of immunotherapy in pancreatic cancer.


[1]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2]Moyer MT,Gaffney RR.Pancreatic adenocarcinoma[J].N Engl J Med,2014,371(22):2139-2141.
[3]Von Hoff DD,Ervin T,Arena FP,et al.Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine[J].N Engl J Med,2013,369(18):1691-1703.
[4]Evans A,Costello E.The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion [J].Front Physiol,2012,3(270):1-7.
[5]Yao S,Zhu Y,Chen L.Advances in targeting cell surface signaling molecules for immune modulation[J].Nat Rev Drug Discov,2013,12(2):130-146.
[6]Yumu Ito,Shunsuke Kondo,Kohei Tada,et al.Clinical development of immune checkpoint inhibitors [J].Biomed Res Int,2015,2015:12.
[7]Royal RE,Levy C,Turner K,et al.Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma [J].J Immunother,2010,33(8):828-833.
[8]Nivolumab Borghaei H,Paz-Ares L,Horn L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer [J].N Engl J Med,2015,373(17):1627-1639.
[9]Robert C,Schachter J,Long GV,et al.Pembrolizumab versus ipilimumab in advanced melanoma [J].N Engl J Med,2015,372(26):2521-2532.
[10]Brahmer JR,Tykodi SS,Chow LQ,et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer [J].N Engl J Med,2012,366(26):2455-2465.
[11]Leventakos K,Mansfield AS.Advances in the treatment of non-small cell lung cancer:Focus on nivolumab,pembrolizumab,and atezolizumab [J].Bio Drugs,2016,30(5):397-405.
[12]Hardacre JM,Mulcahy M,Small W,et al.Addition of algenpentucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer:a phase 2 study [J].J Gastrointest Surg,2013,17(1):94-100.
[13]Lutz E,Yeo CJ,Lillemoe KD.A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma.A Phase II trial of safety,efficacy,and immune activation [J].Ann Surg,2011,253(2):328-335.
[14]T Le,Andrea Wang-Gillam,Vincent Picozzi.Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer dung [J].J Clin Oncol,2015,33(12):1325-1333.
[15]Ruden M,Puri N.Novel anticancer therapeutics targeting telomerase [J].Cancer Treat Rev,2013,39(5):444-456.
[16]Lucia Picariello,Cecilia Grappone,Simone Polvani,et al.Telomerase activity:An attractive target for cancer therapeutics[J].World J Pharmacol,2014,3(4):86-96.
[17]Bernhardt SL,Gjertsen MK,Trachsel S,et al.Telomerase peptide vaccination of patients with non-resectable pancreatic cancer:a dose escalation phase I/II study [J].Br J Cancer,2006,95(11):1474-1482.
[18]Middleton G,Silcocks P,Cox T,et al.Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac):an open-label,randomized,phase 3 trial [J].Lancet Oncol,2014,15(8):829-840.
[19]Zhang C,Hu B,Xiao L,et al.Pseudotying lentiviral vectors with lympgocytic choriomening it is virus glycoproteins for transduction of dendritic cells and in vivo immunization[J].Human Gene Therapy Methods,2014,25(6):328-338.
[20]Kimura Y,Tsukada J,Tomoda T,et al.Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma [J].Pancreas,2012,41(2):195-205.
[21]Ramos CA,Dotti G.Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy[J].Expert Opin Biol Ther,2011,11(7):855-873.
[22]Chang K,Pastan I.Molecular cloning of mesothelin,a differentiation antigen present on mesothelium,mesotheliomas,and ovarian cancers[J].Proc Natl Acad Sci USA,1996,93(1):136-140.
[23]Beatty GL,Haas AR,Maus MV,et al.Mesothelin-specific chimeric antigen receptor mRNA engineered T cells induce anti-tumor activity in solid malignancies.Cancer Immunol Res,2014,2(2):112-120.
[24]Porter DL,Levine BL,Kalos M,et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J].N Engl J Med,2011,365(8):725-733.
[25] Maus MV,Haas AR,Beatty GL,et al.T cells expressing chimeric antigen receptors can cause anaphylaxis in humans[J].Cancer Immunol Res,2013,1(1):26-31.
[26]Gold DV,Modrak DE,Schutsky K,et al.Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft[J].Int J Can,2004,109(4):618-626.
[27]Ocean AJ,Pennington KL,Guarino MJ,et al.Fractionated radio immunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer:a phase 1 trial[J].Cancer,2012,118(22):5487-5506.
[28]Nedaeinia R,Avan A,Manian M,et al.EGFR as a potential target for treatment of pancreatic cancer:dilemma and controversies[J].Curr Drug Targets,2014,15(14):1298-1301.
[29]Philip PA,Benedetti J,Corless CL,et al.Phase III study in comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma:southwest oncology group-directed intergroup trial S0205[J].J Clin Oncol,2010,28(22):3605-3610.
[30]Saxby AJ,Nielsen A,Scarlett CJ,et al.Assessment of HER-2 status in pancreatic adenocarcinoma:correlation of immunohistochemistry,quantitative realtime RT-PCR,and FISH with aneuploidy and survival[J].Am J Surg Pathol,2005,29(9):1125-1134.
[31]Pratesi G,Petrangolini G,Tortoreto M,et al.Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu[J].J Immunother,2008,31(6):537-544.
[32]Assenat E,Azria D,Mollevi C,et al.Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure:results of the "THERAPY" phase 1-2 trial[J].Oncotarget,2015,6(14):12796-12808.
[33]Kindler HL,Niedzwiecki D,Hollis D,et al.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer:phase III trial of the cancer and leukemia group B (CALGB 80303) [J].J Clin Oncol,2010,28(22):3617-3622.
[34]Bellone G,Smirne C,Mauri FA,et al.Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens:implications for survival[J].Cancer Immunol Immunother,2006,55(6):684-698.
[35]Chard LS,Lemoine NR,Wang Y.New role of Interleukin-10 in enhancing antitumor efficacy of oncolytic vaccinia virus for the treatment of pancreatic cancer[J].Oncoimmunology,2015,4(9):e1038689.
[36]Wu HH,Hwang-Verslues WW,Lee WH,et al.Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines[J].J Exp Med,2015,212(3):333-349.
[37]Le DT,Lutz E,Uram JN,et al.Evaluation of Ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer[J].J Immunother,2013,36(7):382-389.
[38]Rafael Winograd,Katelyn T Byrne,Rebecca A Evans,et al.Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma[J].Cancer Immunol Res,2015,3(4):399-411.


Last Update: 2017-04-01